If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 181 - 190 of 278
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination with Ruxolitinib in Participants with Newly Diagnosed Chronic Graft-Versus-Host Disease
Objective
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Protocol No
INCYTE-INCA-34176-254
Categories
Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia
Objective
Study of ziftomenib in combination with venetoclax or chemotherapy for treatment of AML patients
Protocol No
KURA-KO-MEN-007
Categories
A Prospective, Single-arm, Multi-center, Open-label Trial Evaluating the Continuous Application of Prevena Therapy for up to 14 Days
Objective
Continuous Treatment With PREVENA Therapy for 14 Days
Protocol No
SURG-3M-PREVENA
Categories
Multicenter, Double-blind, Randomized, Placebo Controlled, Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301), in Patients With Severe Traumatic Brain Injury (TBI).
Objective
Study to Assess the Safety of Amantadine Hydrochloride IV Solution in Patients With Severe TBI
Protocol No
NEURO-SHINKEI-TBI
Impella-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function: The PROTECT IV Trial
Objective
Impella-Supported PCI in Complex Coronary Artery Disease PROTECT IV
Protocol No
CVC-ABIOMED-PROTECT-IV
Categories
A Randomized, Masked, Placebo Controlled, Phase II Trial of Concurrent Chemoradiation with BMX-001 in Patients with Head and Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation
Objective
Study of BMX-001 radioprotector with chemoradiation therapy for H/N cancer patients
Protocol No
NRG-CC013
Categories
A Phase I Study of Hypofractionated Preoperative Radiation for Head and Neck Cancers (HyPR-HN)
Objective
In this study, we want to find out whether the reduction of the radiation treatment fractions (to 10, 7, or 5 instead of 30) with a higher dose per fraction may be delivered in resected Head and Neck Squamous Cell Carcinoma patients.
Protocol No
IIT-ZENGA-HYPR-HN
Categories
Hand Function as a Biomarker of Brain Tumor Motor Cortical Involvement
Objective
Hand Function in Brain Tumors
Protocol No
IIT-KRUCOFF-HAND-FUNCTION
Categories
A Phase 3 Randomized, Open-Label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Next-generation Hormonal Agent (NHA) and Tax
Objective
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Protocol No
MERCK-MK-5684-003
Categories
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib vs Physicians Choice in Subjects with FGFR-Altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma
Objective
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (FIRST-308)
Protocol No
TRANSTHERA-TT420C2308
Categories